FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4281932421> ?p ?o ?g. }

• W4281932421 endingPage "TPS11594" @default.
• W4281932421 startingPage "TPS11594" @default.
• W4281932421 abstract "TPS11594 Background: Anti-PD 1/PD-L1 blockade alone or in combination with anti-CTLA4 have yielded suboptimal results in most sarcoma subtypes. CD73, an ectonucleotidase, catalyzes the rate-limiting step for adenosine production in the extracellular space, which then aids tumors in evading immune recognition and destruction. Oleclumab, a monoclonal antibody (mAb) selectively binds and inhibits the activity of CD73, and preclinical data suggests additive activity with durvalumab, a mAb that blocks PD-L1. We designed a trial combining oleclumab and durvalumab in certain sarcoma subtypes, selected based on modest activity with anti-PDL-1 and intense staining with CD73 in the tumor microenvironment. Methods: This phase 2 study (NCT04668300) is enrolling patients with age ≥18 years with recurrent/metastatic angiosarcoma (cohort 1) or dedifferentiated liposarcoma (DLPS) (cohort 2) and ≥12 years with recurrent/metastatic osteosarcoma (cohort 3), who have received at least one prior systemic therapy but are checkpoint inhibitor naïve and have measurable disease. Each treatment cycle is 28 days with oleclumab administered at 3000 mg i.v. every 2 weeks x 5 doses, and then every 4 weeks and durvalumab administered at 1500 mg i.v every 4 weeks. Tumor assessments are based on RECIST 1.1 and immune-related response criteria (irRC) and performed at baseline, and every 8 weeks after start of therapy, with an additional scan at 12 weeks for confirmation of response. Planned sample size is ≤ 25 pts in each arm. The primary efficacy endpoint for cohorts 1 and 2 is response rate (RR) at 4 months (per RECIST 1.1). The primary efficacy endpoint for cohort 3 is event free survival (EFS) rate at 4 months. If there is a high probability that the RR4 months is unlikely to be at least 20% for cohorts 1 and 2 or the EFS4 months is unlikely to be at least 40% for cohort 3 then the accrual of the corresponding cohort will be halted. The cohorts will be monitored separately for both futility and toxicity in groups of 5 after a minimum of 10 patients have been enrolled in each cohort. Secondary endpoints for the study include safety, best RR by RECIST and irRC, median PFS, and OS. Core needle biopsies and blood samples are collected at baseline and early on-treatment (week 6). Fresh flow cytometry is being performed to assess changes in T-cell activation, proliferation, and function and CD73 expression in the membrane and cytoplasm is being assessed by immunohistochemistry. Localization of tumor-infiltrating lymphocytes and engagement of the PD-1/PDL1 axis is being assessed using multiplex immunofluorescence staining. As of Jan 30th, 2022, twenty-two patients have initiated study treatment, 3 in cohort 1, 12 in cohort 2, and 7 in cohort 3. Clinical trial information: NCT04668300." @default.
• W4281932421 created "2022-06-13" @default.
• W4281932421 creator A5002293304 @default.
• W4281932421 creator A5009886411 @default.
• W4281932421 creator A5014340135 @default.
• W4281932421 creator A5017340875 @default.
• W4281932421 creator A5032743242 @default.
• W4281932421 creator A5033777229 @default.
• W4281932421 creator A5043477787 @default.
• W4281932421 creator A5054595254 @default.
• W4281932421 creator A5063272827 @default.
• W4281932421 creator A5065709859 @default.
• W4281932421 creator A5071575774 @default.
• W4281932421 creator A5071747925 @default.
• W4281932421 creator A5074671045 @default.
• W4281932421 creator A5079077130 @default.
• W4281932421 creator A5083143523 @default.
• W4281932421 creator A5086634878 @default.
• W4281932421 creator A5087234749 @default.
• W4281932421 creator A5089849331 @default.
• W4281932421 date "2022-06-01" @default.
• W4281932421 modified "2023-10-02" @default.
• W4281932421 title "A phase II multi-arm study to test the efficacy of oleclumab and durvalumab in specific sarcoma subtypes." @default.
• W4281932421 doi "https://doi.org/10.1200/jco.2022.40.16_suppl.tps11594" @default.
• W4281932421 hasPublicationYear "2022" @default.
• W4281932421 type Work @default.
• W4281932421 citedByCount "3" @default.
• W4281932421 countsByYear W42819324212023 @default.
• W4281932421 crossrefType "journal-article" @default.
• W4281932421 hasAuthorship W4281932421A5002293304 @default.
• W4281932421 hasAuthorship W4281932421A5009886411 @default.
• W4281932421 hasAuthorship W4281932421A5014340135 @default.
• W4281932421 hasAuthorship W4281932421A5017340875 @default.
• W4281932421 hasAuthorship W4281932421A5032743242 @default.
• W4281932421 hasAuthorship W4281932421A5033777229 @default.
• W4281932421 hasAuthorship W4281932421A5043477787 @default.
• W4281932421 hasAuthorship W4281932421A5054595254 @default.
• W4281932421 hasAuthorship W4281932421A5063272827 @default.
• W4281932421 hasAuthorship W4281932421A5065709859 @default.
• W4281932421 hasAuthorship W4281932421A5071575774 @default.
• W4281932421 hasAuthorship W4281932421A5071747925 @default.
• W4281932421 hasAuthorship W4281932421A5074671045 @default.
• W4281932421 hasAuthorship W4281932421A5079077130 @default.
• W4281932421 hasAuthorship W4281932421A5083143523 @default.
• W4281932421 hasAuthorship W4281932421A5086634878 @default.
• W4281932421 hasAuthorship W4281932421A5087234749 @default.
• W4281932421 hasAuthorship W4281932421A5089849331 @default.
• W4281932421 hasConcept C121608353 @default.
• W4281932421 hasConcept C126322002 @default.
• W4281932421 hasConcept C142724271 @default.
• W4281932421 hasConcept C143998085 @default.
• W4281932421 hasConcept C203092338 @default.
• W4281932421 hasConcept C2777701055 @default.
• W4281932421 hasConcept C2777742743 @default.
• W4281932421 hasConcept C2778256501 @default.
• W4281932421 hasConcept C2780030458 @default.
• W4281932421 hasConcept C535046627 @default.
• W4281932421 hasConcept C71924100 @default.
• W4281932421 hasConcept C72563966 @default.
• W4281932421 hasConceptScore W4281932421C121608353 @default.
• W4281932421 hasConceptScore W4281932421C126322002 @default.
• W4281932421 hasConceptScore W4281932421C142724271 @default.
• W4281932421 hasConceptScore W4281932421C143998085 @default.
• W4281932421 hasConceptScore W4281932421C203092338 @default.
• W4281932421 hasConceptScore W4281932421C2777701055 @default.
• W4281932421 hasConceptScore W4281932421C2777742743 @default.
• W4281932421 hasConceptScore W4281932421C2778256501 @default.
• W4281932421 hasConceptScore W4281932421C2780030458 @default.
• W4281932421 hasConceptScore W4281932421C535046627 @default.
• W4281932421 hasConceptScore W4281932421C71924100 @default.
• W4281932421 hasConceptScore W4281932421C72563966 @default.
• W4281932421 hasIssue "16_suppl" @default.
• W4281932421 hasLocation W42819324211 @default.
• W4281932421 hasOpenAccess W4281932421 @default.
• W4281932421 hasPrimaryLocation W42819324211 @default.
• W4281932421 hasRelatedWork W2315085516 @default.
• W4281932421 hasRelatedWork W2316407790 @default.
• W4281932421 hasRelatedWork W2416044440 @default.
• W4281932421 hasRelatedWork W2603773853 @default.
• W4281932421 hasRelatedWork W2947816590 @default.
• W4281932421 hasRelatedWork W2964295425 @default.
• W4281932421 hasRelatedWork W3021216473 @default.
• W4281932421 hasRelatedWork W4362584161 @default.
• W4281932421 hasRelatedWork W4377938984 @default.
• W4281932421 hasRelatedWork W4379280921 @default.
• W4281932421 hasVolume "40" @default.
• W4281932421 isParatext "false" @default.
• W4281932421 isRetracted "false" @default.
• W4281932421 workType "article" @default.